Evidence map›Paper›PMID 30223472›Full record

ArticleInternational journal of molecular sciences2018

Lucia Ansani, Jlenia Marchesini, Gabriele Pestelli, Giovanni Andrea Luisi, Giulia Scillitani, Giovanna Longo, Daniela Milani, Maria Luisa Serino, Veronica Tisato, Donato Gemmati

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Genes · 2021
    Article
  8. Article
  9. Review
  10. "International journal of molecular sciences · 2019
    Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lucia AnsaniOperative Unit of Cardiology, University Hospital S. Anna of Ferrara, 44121 Ferrara, Italy. l.ansani@ospfe.it.ORCID 0000-0001-5511-0133
Jlenia MarchesiniOperative Unit of Cardiology, University Hospital S. Anna of Ferrara, 44121 Ferrara, Italy. jlenia.marchesini@unife.it.
Gabriele PestelliOperative Unit of Cardiology, University Hospital S. Anna of Ferrara, 44121 Ferrara, Italy. gabriele.pestelli@unife.it.
Giovanni Andrea LuisiOperative Unit of Cardiology, University Hospital S. Anna of Ferrara, 44121 Ferrara, Italy. giovanniandrea.luisi@unife.it.
Giulia ScillitaniOperative Unit of Cardiology, University Hospital S. Anna of Ferrara, 44121 Ferrara, Italy. giulia.scillitani@unife.it.
Giovanna LongoCentre of Haemostasis & Thrombosis, Department of Biomedical and Specialty Surgical Sciences, Section of Medical Biochemistry, Molecular Biology & Genetics, University of Ferrara, 44121 Ferrara, Italy. giovanna.longo@student.unife.it.
Daniela MilaniDepartment of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy. daniela.milani@unife.it.
Maria Luisa SerinoCentre of Haemostasis & Thrombosis, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy. maria.luisa.serino@unife.it.
Veronica TisatoDepartment of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy. veronica.tisato@unife.it.ORCID 0000-0001-8448-066X
Donato GemmatiCentre of Haemostasis & Thrombosis, Department of Biomedical and Specialty Surgical Sciences, Section of Medical Biochemistry, Molecular Biology & Genetics, University of Ferrara, 44121 Ferrara, Italy. d.gemmati@unife.it.ORCID 0000-0001-6213-6120

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Factor XIIIA (FXIIIA) levels are independent predictors of early prognosis after acute myocardial infarction (AMI) and the Valine-to-Leucine (V34L) single nucleotide polymorphism (SNP) seems associated with lower AMI risk. Since the long-term AMI prognosis merits deeper investigation, we performed an observational study evaluating relationships between FXIIIA residual levels, cardiovascular risk-factors, and inherited genetic predispositions. FXIIIA V34L was genotyped in 333 AMI patients and a five-year follow-up was performed. FXIIIA levels assessed at day-zero (d0) and four days after AMI (d4), and conventional risk factors were analyzed, focusing on the development of major adverse cardiovascular events (MACE). FXIIIA assessed at d0 and d4 was also an independent MACE predictor in the long-term follow-up (FXIIIA

Indexed as

MutationAgedBiomarkersCoronary AngiographyElectrocardiographyFactor XIIIaGenotypeHeart Function TestsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPostoperative PeriodPrognosisBiomarkersFactor XIIIacoagulation factor XIIIleft ventricular remodeling and heart failuremyocardial healingmyocardial infarctionpharmacogeneticsprognostic biomarkerstranslation cardioprotective strategies

Identifiers

PMID30223472
PMCPMC6165350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.